Kanaph Therapeutics Inc. (KOSDAQ:0082N0)

Market Cap	482.61B
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	12.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	278,262
Average Volume	2,891,544
Open	42,000
Previous Close	41,200
Day's Range	35,150 - 42,250
52-Week Range	35,150 - 70,000
Beta	n/a
RSI	n/a
Earnings Date	n/a

About Kanaph Therapeutics

Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecific Fc-fusion protein that combines a C3b blocker and a VEGF blocker ther...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2019
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 0082N0